Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Monte Rosa Therapeutics Inc GLUE

Healthcare Biotechnology
Monte Rosa Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing a portfolio of novel and molecular glue degraders (MGDs). MGDs are small molecule drugs that employ the body’s natural protein destruction mechanisms to selectively degrade therapeutically relevant proteins. It has developed a proprietary and industry leading discovery engine, called... see more

Recent & Breaking News (NDAQ:GLUE)

Monte Rosa Therapeutics Provides Development Progress Updates on MRT-2359 and MRT-6160

GlobeNewswire June 27, 2024

Monte Rosa Therapeutics Presents Preclinical Data at EULAR 2024 Demonstrating Therapeutic Potential of MRT-6160 for the Treatment of Rheumatoid Arthritis

GlobeNewswire June 14, 2024

Monte Rosa Therapeutics Announces Leadership Team Promotions

GlobeNewswire May 30, 2024

Monte Rosa Therapeutics to Present at the Jefferies Global Healthcare Conference

GlobeNewswire May 30, 2024

Monte Rosa Therapeutics Presents Preclinical Data at Digestive Disease Week 2024 Highlighting Therapeutic Potential of MRT-6160 in Inflammatory Bowel Disease

GlobeNewswire May 21, 2024

Monte Rosa Therapeutics Announces Pricing of $100 Million Underwritten Public Offering

GlobeNewswire May 16, 2024

Monte Rosa Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

GlobeNewswire May 15, 2024

Monte Rosa Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update

GlobeNewswire May 9, 2024

Monte Rosa Therapeutics Announces the Departure of Owen Wallace, Ph.D., Chief Scientific Officer

GlobeNewswire May 2, 2024

Monte Rosa Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

GlobeNewswire March 14, 2024

Monte Rosa Therapeutics Announces Initiation of IND Enabling Studies for MRT-8102, A First-in-Class NEK7 Directed Molecular Glue Degrader and NLRP3/IL-1β Pathway Inhibitor

GlobeNewswire March 11, 2024

Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences

GlobeNewswire January 31, 2024

Monte Rosa Therapeutics Provides Corporate Update and Key Anticipated Milestones for 2024

GlobeNewswire January 8, 2024

Monte Rosa Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference

GlobeNewswire January 3, 2024

Monte Rosa Therapeutics to Present at Piper Sandler Healthcare Conference

GlobeNewswire November 21, 2023

Monte Rosa Therapeutics Announces Third Quarter 2023 Financial Results and Provides Corporate Update

GlobeNewswire November 9, 2023

Monte Rosa Therapeutics Presents Preclinical Data at ACR Convergence 2023 Demonstrating Potential of MRT-6160, a VAV1-targeted Molecular Glue Degrader, to Treat Immunological and Inflammatory Diseases

GlobeNewswire November 7, 2023

Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences

GlobeNewswire October 27, 2023

Monte Rosa Therapeutics Announces $25 Million Registered Direct Offering, Priced At- the-Market Under Nasdaq Rules

GlobeNewswire October 26, 2023

Monte Rosa Therapeutics Announces Interim PK/PD and Clinical Data for MRT-2359 in Phase 1/2 Trial for MYC-Driven Solid Tumors

GlobeNewswire October 17, 2023